Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss

Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss

Conference call will take place on Wednesday, July 15, 2026 at 8:00 am ET

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Wednesday, July 15, 2026 at 8:00 am ET to review results from female treatment arms of the Phase 2 open-label Study ‘207’ evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males and females with mild-to-moderate pattern hair loss.

Webcast Details:

Time: Wednesday, July 15, 2026 at 8:00 a.m. ET.